A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma

NCT05864924 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

EBV-positive Nasopharyngeal Carcinoma

Interventions

BIOLOGICAL: Cohort A: 3.0x10^6 CAR-T cells/kg
BIOLOGICAL: Cohort B: 9.0x10^6CAR-T cells/kg
BIOLOGICAL: Cohort C:1.5x10^7 CAR-T cells /kg

Sponsor

BioSyngen Pte Ltd